Latest News

• 
  All Medical News

  ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

  Written by Alex Burton | 14 Jan 2019

  Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.

• 
  All Medical News

  Advanced stage disease

  Written by Karen Ramirez | 5 Dec 2018

  As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.

• 
  All Medical News

  UEGW 2018: Clinical trials in IBD – late-breaking abstracts

  Written by Alex Burton | 4 Nov 2018

  Among the late-breaking clinical trial abstracts at UEG Week were new data for ustekinumab in UC, a new formulation for subcutaneous administration of vedolizumab, and early clinical data… read more.

• 
  All Medical News

  UEGW 2018: Future therapies in IBD

  Written by Alex Burton | 3 Nov 2018

  Professor Stefan Schreiber (Germany) discusses  the future of therapies in IBD.

• 
  All Medical News

  UEGW 2018: Debate: Treat to target and tight monitoring in IBD

  Written by Alex Burton | 2 Nov 2018

  Dr Filip Baert (Belgium) discusses the debate at UEGW on treating to target and tight monitoring in IBD.

• 
  All Medical News

  UEGW 2018: IBD: from epidemiology to costs and outcome

  Written by Alex Burton | 1 Nov 2018

  Dr Johan Burisch (Denmark) reviews data he presented on the cost saving effect of biological therapy in patients with IBD.

• 
  All Medical News

  WCLC 2018: Variety of approaches can work in oligometastatic disease

  Written by Karen Ramirez | 17 Oct 2018

  Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.

• 
  All Medical News

  WCLC 2018: Lung cancer stigma is detrimental to patient care

  Written by Karen Ramirez | 17 Oct 2018

  Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients’ care.

• 
  All Medical News

  WCLC 2018: Importance of QOL outcome measures in clinical trials

  Written by Karen Ramirez | 17 Oct 2018

  WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.

• 
  All Medical News

  WCLC 2018: Accessibility & quality of life: a patient focus at WCLC

  Written by Karen Ramirez | 17 Oct 2018

  Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said… read more.

• 
  All Medical News

  WCLC 2018: PACIFIC: durvalumab results impressive, but not without questions

  Written by Karen Ramirez | 17 Oct 2018

  Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.

• 
  All Medical News

  WCLC 2018: Early ALTA-1L data encouraging for brigatinib

  Written by Karen Ramirez | 17 Oct 2018

  The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with… read more.